Skip to content

Continuous Infusion and Intermittent Bolus Adductor Canal Block for Total Knee Arthroplasty

Continuous Infusion and Intermittent Bolus Adductor Canal Block for Total Knee Arthroplasty

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05518513
Enrollment
66
Registered
2022-08-26
Start date
2022-11-01
Completion date
2024-09-30
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adductor Canal Block, Arthroplasty, Replacement, Knee

Keywords

total knee arthroplasty, adductor canal block, nerve block, regional analgesia

Brief summary

The investigators believed the analgesic efficacy of adductor canal block on patients receiving total knee arthroplasty. However, the analgesic effects of different delivery regimens and duration of effects are variable. The investigators hypothesize that using continuous infusion and shorter interval bolus of local anesthetics to perform adductor canal block will reduce pain scale and opioid consumption in patients receiving total knee arthroplasty compared with longer interval bolus of local anesthetics.

Detailed description

Sensory innervations contributing pain after total knee arthroplasty (TKA) include branches of femoral, obturator and sciatic nerves. Branches of femoral nerve contribute the most pain sensation in TKA including nerves to the vastus medialis, intermedius, and lateralis, medial and intermediate femoral cutaneous, and saphenous nerves. Smaller contribution of pain sensation from branches of fibular and tibial nerves, and posterior branch of obturator nerve. Multiple techniques of nerve block could anesthetize some or all of the sensory innervations, but analgesia with motor sparing is important for early recovery and rehabilitation after TKA. For both pain reduction and motor function, adductor canal block (ACB) combined with local infiltration analgesia is considered more feasible than other peripheral nerve blocks. ACB could anesthetize nerves beyond in adductor canal. Anatomical studies revealed the extended spreading of local anesthetics (LA) beyond adductor canal when performing ACB, and caudal spreading could reach popliteal fossa through adductor hiatus. Cephalad spreading of LA in ACB is limited and rarely extending to femoral triangle even when injecting from proximal adductor canal, but the cephalad spreading also depends on the volume of injectants and using tourniquets. In clinical studies, both ACB injection site and volume of injectants were investigated. Clinical trials and systematic reviews revealed the similar efficacy of analgesia when ACB injection at proximal and distal adductor canal, although the volume and pattern of injection (bolus or continuous) were variable. Regarding to the volume of injectants, 20ml injectant of local anesthetics would be adequate without prominent motor impairment compared with smaller volume. Previous systematic reviews and meta-analysis have confirmed better analgesia with continuous infusion of ACB than single shot, but few studies explored the difference of intermittent bolus and continuous infusion. One clinical trial compared continuous infusion and intermittent bolus of ACB in patients receiving TKA, two other trials investigated the difference in healthy volunteers and patients receiving knee arthroscopy. All these three studies concluded no difference of analgesic efficacy. However, no consistent volume and frequency of injection was studied. Whether longer interval of intermittent bolus was the same with continuous infusion in analgesic efficacy is still need to be further verified.

Interventions

DRUGBupivacain

adductor canal block with 0.25% bupivacaine

Sponsors

National Cheng-Kung University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults receiving unilateral total knee arthroplasty under spinal anesthesia * American society of anesthesiologists 1-3

Exclusion criteria

* Could not cooperate * Allergy to medicines used in the study * Chronic pain * Long term opioid use * Neuromuscular disease * Surgical complication: massive bleeding, postoperative ICU, unanticipated procedure

Design outcomes

Primary

MeasureTime frameDescription
Accumulated morphine consumptionIn postoperative 48 hoursAdditional morphine prescription

Secondary

MeasureTime frameDescription
Numerical pain scale at restIn postoperative 2 daysFrom no pain felt as 0 to the most pain felt as 10, measuring pain score at postoperative care unit, 3/9 pm on operative day, 9 am and 3/9 pm on postoperative day 1, 9 am and 3/9 pm on postoperative day 2
Numerical pain scale during knee flexionIn postoperative 2 daysFrom no pain felt as 0 to the most pain felt as 10, measuring pain score at postoperative care unit, 3/9 pm on operative day, 9 am and 3/9 pm on postoperative day 1, 9 am and 3/9 pm on postoperative day 2
Percentage of muscle power decrementIn postoperative 2 daysExtension strength of thigh at surgical side, measurement before surgery and postoperatively, access by dynameter as participants sit and perform surgical leg thigh extension, assessing at 9 am on postoperative day 1 and 2
Postoperative nausea and vomitingIn postoperative 2 daysAccess if any sensation of nausea or episodes of vomiting
Event of falling downIn postoperative 2 daysRecord the number of events of falling down

Other

MeasureTime frameDescription
Opioid related side effectIn postoperative 2 daysRecord if any sensation of urinary retention, skin pruritus
Nerve block related complicationIn postoperative 2 daysRecord if any episode of nerve block insertion site hematoma, leakage of local anesthetics, or local anesthetic systemic toxicity

Countries

Taiwan

Contacts

Primary ContactWei-Teng Weng, MD
n100390@mail.hosp.ncku.edu.tw+886-6-2353535
Backup ContactChung-Ren Lin, MD.PhD.
n104065@mail.hosp.ncku.edu.tw+886-6-2353535

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026